BBIO Q4 2019 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M

Gross Profit

$14M100.0% margin

Operating Income

-$79M-569.1% margin

Net Income

-$73M-531.6% margin

EPS (Diluted)

$-0.62

QoQ Revenue Growth

-48.3%

Cash Flow

Operating Cash Flow

-$76M

Free Cash Flow

-$78M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$632M

Total Liabilities

$156M

Stockholders' Equity

$408M

Cash & Equivalents

$364M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$0	—
Gross Profit	$14M	$0	—
Operating Income	-$79M	-$66M	-19.9%
Net Income	-$73M	-$39M	-90.1%